SCHEMBL3019912

SCHEMBL3019912

N#Cc1ccccc1S(=O)(=O)C1CCN(c2nc(-c3cc(F)cc(Cl)c3)cs2)CC1

nearest known ligand 0.45

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 1/20 0.45
HTR2A P28223 1/20 0.45
HTR2C P28335 1/20 0.45
KCNH2 Q12809 1/20 0.45
SMN1; SMN2 Q16637 6/20 0.43
RAB9A P51151 5/20 0.43
CTSS P25774 6/20 0.42
MAPT P10636 2/20 0.41
ALDH1A1 P00352 2/20 0.41
MEN1 O00255 2/20 0.41
LMNA P02545 2/20 0.41
KMT2A Q03164 2/20 0.41
NPC1 O15118 4/20 0.39
L3MBTL1 Q9Y468 3/20 0.39
CYP1A2 P05177 2/20 0.39
CYP2C9 P11712 2/20 0.39
CYP2C19 P33261 2/20 0.39
CYP3A4 P08684 1/20 0.39
MAPK1 P28482 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3007958 0.95 RAB9A (0.47) DRD2HTR2AHTR2CKCNH2SMN1; SMN2
SCHEMBL3012487 0.94 DRD2 (0.48) DRD2HTR2AHTR2CKCNH2SMN1; SMN2
SCHEMBL3009205 0.88 SMN1; SMN2 (0.48) SMN1; SMN2RAB9ACTSSMAPTALDH1A1
SCHEMBL2999922 0.88 DRD2 (0.45) DRD2HTR2AHTR2CKCNH2SMN1; SMN2
SCHEMBL3014741 0.87 MAPT (0.52) SMN1; SMN2RAB9ACTSSMAPTALDH1A1
SCHEMBL3014897 0.87 SMN1; SMN2 (0.45) SMN1; SMN2RAB9ACTSSMAPTALDH1A1
SCHEMBL3017075 0.87 DRD2 (0.47) DRD2HTR2AHTR2CKCNH2SMN1; SMN2
SCHEMBL3017676 0.86 DRD2 (0.45) DRD2HTR2AHTR2CKCNH2SMN1; SMN2
SCHEMBL3004893 0.86 ALDH1A1 (0.55) HTR2AHTR2CSMN1; SMN2RAB9AMAPT
SCHEMBL3011288 0.85 LMNA (0.52) KCNH2SMN1; SMN2RAB9ACTSSMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA DRD2 573/4885HTR2A 752/4885HTR2C 1153/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.